Jenburkt Pharma - Jenburkt Pharma

📊 BSE: 524731 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

💰 Financial Performance

Revenue Growth by Segment

The company operates exclusively in the pharmaceutical formulations segment, which generated total revenue of INR 15,841.25 Lacs in FY 2024-25, representing a growth of 8.03% YoY from INR 14,663.34 Lacs in FY 2023-24.

Geographic Revenue Split

Not specifically disclosed by percentage, but the company maintains a presence in both domestic Indian markets and international regions, noting a temporary slowdown in certain international markets due to currency fluctuations and import restrictions.

Profitability Margins

Operating profit margin improved significantly from 25.05% in FY 2023-24 to 29.32% in FY 2024-25. Net profit margin also saw an upward trend, increasing from 18.30% to 21.14% over the same period due to better operational philosophy and performance-driven models.

EBITDA Margin

Operating profit margin (a proxy for core profitability) stood at 29.32% for FY 2024-25, a YoY increase of 427 basis points from 25.05%, driven by a strategic organizational refresh and improved agility.

Capital Expenditure

Not disclosed in absolute INR Cr; however, the company states that profits are ploughed back into the business every year to fund strategic and diversified investments, research and development, and sustainable growth.

Credit Rating & Borrowing

CRISIL withdrew the rating for bank loan facilities of INR 70 Million in 2014 at the company's request as there were no outstanding dues. The company remains virtually debt-free with a total Debt-Equity Ratio of only 0.02 times in FY 2024-25.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) are the primary raw materials; specific percentage of total cost is not disclosed, but they represent the core input for pharmaceutical formulations.

Import Sources

China is specifically identified as a critical source for Active Pharmaceutical Ingredients (APIs), creating a strategic vulnerability due to potential export restrictions.

Capacity Expansion

Current installed capacity is not disclosed in MT/units; however, the company is modernizing operations through the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme (RPTUAS) to meet international standards.

Raw Material Costs

Not disclosed as a specific percentage of revenue; however, the company notes that dependence on China for APIs could escalate costs by 20-30% if supply disruptions or resource nationalism occur.

Manufacturing Efficiency

The company operates a manufacturing unit at Sihor, Gujarat; specific utilization percentages are not disclosed, but the company is implementing Artwork Management software to digitize manual processes and reduce approval timelines.

Logistics & Distribution

Not disclosed as a specific percentage of revenue; however, the company emphasizes prompt payment to vendors to ensure a smooth supply chain.

📈 Strategic Growth

Expected Growth Rate

8-10%

Growth Strategy

Growth will be achieved through a strategic organizational refresh focused on Teamwork, Performance, and Agility. This includes launching new products (4 launched in FY 2024-25), international expansion, and digital transformation via AI/ML in drug discovery and Artwork Management software to reduce operational lead times.

Products & Services

Speciality pharmaceutical formulations, healthcare products, and medicines focused on pain management, oncology, neurology, and chronic diseases.

Brand Portfolio

Jenburkt

New Products/Services

Launched 2 new products in the Pharmaceutical Division and 2 new products in the Wellness Division during FY 2024-25.

Market Expansion

Focusing on international business prospects and becoming a globally recognized healthcare brand by engaging with local partners in export markets.

Market Share & Ranking

Not disclosed; however, India as a whole accounts for 20% of global generic medicine volume.

Strategic Alliances

Engaging with local partners in international markets to ensure business continuity despite temporary demand slowdowns.

🌍 External Factors

Industry Trends

The industry is shifting toward innovation, complex therapies, and digital transformation. The domestic biosimilars market is projected to grow at a 14% CAGR, and the 'China+1' strategy is attracting more contract manufacturing to India.

Competitive Landscape

The industry comprises over 3,000 drug manufacturers; Jenburkt competes on quality and compliance, leveraging its USFDA-approved plant environment in India.

Competitive Moat

Moat is built on 40 years of excellence, a debt-free and cash-rich balance sheet (Net Worth of INR 17,177.71 Lacs), and a renewed R&D certification which provides scientific credibility and financial agility to seize growth opportunities.

Macro Economic Sensitivity

Sensitive to government healthcare spending and the 'Digital Health Blueprint' initiatives; the domestic market is projected to reach USD 58 billion by 2025.

Consumer Behavior

Shifting toward chronic disease treatments and affordable biosimilars due to an aging population and changing disease burden in India.

Geopolitical Risks

Dependence on China for APIs and resource nationalism are cited as major risks that could disrupt production capabilities.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Drugs and Cosmetics Act 1940, Drug (Price Control) Order 2013, and CDSCO quality control measures. The government recently banned 156 fixed-dose combination (FDC) drugs.